WuXi Biologics (02269.HK) Addresses Stock Price Fluctuations and Clarifies Business Operations
In response to unusual fluctuations in the stock price and trading volume of its shares on the Stock Exchange, WuXi Biologics (02269.HK) has issued a statement to clarify its business operations and dispel any rumors.
The company emphasized that it does not have a human genomics business and does not collect human genomic data in its various businesses. Furthermore, the company’s CEO and executive director, Dr. Chen Zhisheng, has not worked for any institution with a military background and has not received any compensation from such institutions.
WuXi Biologics reaffirmed that its business operations remain sound and aligned with its annual and medium-term strategies. The management team expressed confidence in the company’s prospects and does not anticipate any major adverse changes in its business operations and financial condition. As a trusted partner in the global healthcare industry, the company is committed to advancing the discovery, development, and production of biopharmaceuticals to benefit patients worldwide.
Additionally, the company announced that it will continue to engage in share repurchases in accordance with previous announcements.
This statement comes as a response to recent concerns about the company’s business practices. WuXi Biologics aims to reassure investors and stakeholders that it remains committed to upholding the highest standards of integrity and transparency in its operations.
It is worth noting that the content, data, and tools in this article do not constitute investment advice and are for reference only. The financial community has issued a warning to exercise caution when investing in the stock market, as it carries inherent risks.
Investors are advised to conduct their own due diligence and seek professional financial advice before making any investment decisions related to WuXi Biologics (02269.HK).